News
TVGNW
0.0357
-13.35%
-0.0055
Weekly Report: what happened at TVGNW last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at TVGNW last week (1026-1030)?
Weekly Report · 11/02 09:40
Weekly Report: what happened at TVGNW last week (1019-1023)?
Weekly Report · 10/26 09:39
Weekly Report: what happened at TVGNW last week (1012-1016)?
Weekly Report · 10/19 09:39
Weekly Report: what happened at TVGNW last week (1005-1009)?
Weekly Report · 10/12 09:42
Weekly Report: what happened at TVGNW last week (0928-1002)?
Weekly Report · 10/05 09:42
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Barchart · 09/30 15:30
Weekly Report: what happened at TVGNW last week (0921-0925)?
Weekly Report · 09/28 09:39
Weekly Report: what happened at TVGNW last week (0914-0918)?
Weekly Report · 09/21 09:39
Weekly Report: what happened at TVGNW last week (0907-0911)?
Weekly Report · 09/14 09:42
Weekly Report: what happened at TVGNW last week (0831-0904)?
Weekly Report · 09/07 09:39
Weekly Report: what happened at TVGNW last week (0824-0828)?
Weekly Report · 08/31 09:42
Weekly Report: what happened at TVGNW last week (0817-0821)?
Weekly Report · 08/24 09:43
Weekly Report: what happened at TVGNW last week (0810-0814)?
Weekly Report · 08/17 09:43
Weekly Report: what happened at TVGNW last week (0803-0807)?
Weekly Report · 08/10 09:40
Weekly Report: what happened at TVGNW last week (0727-0731)?
Weekly Report · 08/03 09:40
Weekly Report: what happened at TVGNW last week (0720-0724)?
Weekly Report · 07/27 09:43
Weekly Report: what happened at TVGNW last week (0713-0717)?
Weekly Report · 07/20 09:41
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
Barchart · 07/13 21:15
Weekly Report: what happened at TVGNW last week (0706-0710)?
Weekly Report · 07/13 09:42
More
Webull provides a variety of real-time TVGNW stock news. You can receive the latest news about TEVOGEN INC through multiple platforms. This information may help you make smarter investment decisions.
About TVGNW
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.